Abrar and Sunetha are excited to attend EBF yet again…

EBF (European Bioanalysis Forum) was founded in 2006 on the initiative of 12 pharmaceutical companies. The goal was to create a platform for discussions around science, day-to-day procedures, business tools, technologies, and regulatory issues. As of June 2022, the EBF has 75 members. https://bcn.e-b-f.eu/

​Since 2008, the EBF has organized an annual Open Symposium in Barcelona, Spain. This Open Symposium has become a landmark for bioanalytical discussions in Europe and has created a true Forum-like spirit where people meet and openly discuss during sessions and presentations contributing to the development of an open mind in bioanalysis..

Abrar will be presenting on (17 Nov 2022 at 11:00 am) in the session ‘When it’s Neither Large nor Small’ and will be talking about Bioanalysis of Inbetweeners – (Challenges & Solutions). Here is the abstract:

Drug development is constantly changing and in recent years the change from small molecule (NCEs) to large molecule (NBEs) is most significant.  These molecules do not differ just by size but also in how they are made, mode of action and their behaviour in the body.  These large molecules have been becoming increasingly more important, for this reason, there is a large demand and requirement to analyse these molecules in biological matrices for TK and PK/PD purposes.

The physico-chemical properties of peptides traditionally made them difficult to analyse intact using mass spectrometry.  The combination of bio-analyst inexperience and different analytical approaches required to analyse these compounds have slowed down the method development process and timelines in the industry.  This presentation will show the bioanalytical challenges of analysing these molecules by LC-MS/MS with various solutions and their relative merits to overcome these.